墨西哥制药公司的专利趋势
Luis Villafaña-Diaz1, Juan C Perez-Garcia1, Diana Barron-Villaverde1
1Posgrado en Planeación Estratégica y Dirección Tecnológica, Universidad Popular Autónoma del Estado de Puebla, Puebla, CP, 72410, México.
Pharmaceutical patent analyst
|January 10, 2024
概括
墨西哥制药公司拥有软弱的专利制度,几乎没有申请商业价值低的专利. 这项研究分析了2000年至2020年的专利趋势,揭示了该行业缺乏增长和创新.
科学领域:
- 制药科学 制药科学
- 知识产权法 知识产权法 知识产权法
- 创新管理 创新管理
背景情况:
- 墨西哥制药公司的专利活动在很大程度上是未经记录的.
- 了解专利趋势对于评估创新和经济贡献至关重要.
研究的目的:
- 分析2000年至2020年间墨西哥制药公司的专利化趋势.
- 评估这些公司提交的专利的稳定性和商业价值.
主要方法:
- 使用墨西哥工业财产研究所数据库进行了全面的专利搜索.
- 专利使用墨西哥制药公司的特定清单和相关的国际专利分类代码 (A61K,A61P,C07) 来确定专利.
主要成果:
- 墨西哥制药公司在2000年至2020年期间总共提交了266份专利申请.
- 领先的公司包括Liomont,Senosiain和RIMSA,但整体专利数量较低.
- 专利证明了零的技术因素和低的商业因素.
结论:
- 墨西哥制药公司表现出缺陷的专利制度,其特点是停滞和最小的增长.
- 具有重要的商业价值的专利比例很低,这表明市场影响有限.
关键词:
墨西哥 墨西哥 墨西哥 墨西哥公司公司公司公司公司公司公司公司.patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent制药公司的药品.技术转让技术转让技术转让技术转让技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移技术转移趋势 趋势 趋势更多相关视频
06:08Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
Published on: March 11, 2017
10.6K
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.8K
相关概念视频
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Prescription, Nonprescription and Orphan Drugs
734
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
734
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
